Results of OlympiA are practice changing in treatment of breast cancer
Adjuvant olaparib treatment significantly improves invasive disease-free survival in women with BRCA mutation and high-risk HER2-negative breast cancer. With a median follow-up of 2.5 years, olaparib-treated patients had a 42% reduction in the risk of developing invasive relapse compared to placebo.
Få tilgang til artikkelen
Hvis du er lege, sykepleier eller annen helsepersonell, kan du få tilgang til hele artikkelen ved å opprette en profil på BestPractice Nordic.
- Få tilgang
- Hvis du allerede har en profil: Logg in
